background
sever
acut
respiratori
syndrom
sar
result
hundr
infect
death
global
aim
assess
immunogen
protect
efficaci
purifi
inactiv
verocel
sar
vaccin
monkey
method
cultur
sar
coronaviru
sarscov
strain
infect
vero
cell
inactiv
sequenti
procedur
includ
ultrafiltr
gel
filtrat
ion
exchang
chromatographi
perform
obtain
purifi
inactiv
sar
vaccin
purifi
sar
vaccin
analyz
electron
microscop
hplc
western
blot
immun
three
group
cynomolgu
macaqu
fasciculari
adjuvantcontain
purifi
vaccin
purifi
vaccin
unpurifi
vaccin
respect
fourth
group
serv
control
antibodi
titer
measur
plaqu
reduct
neutral
test
vaccin
monkey
challeng
sarscov
strain
observ
protect
efficaci
addit
three
group
rhesu
monkey
immun
differ
dose
purifi
inactiv
sar
vaccin
gtimemonkey
day
monkey
challeng
sarscov
strain
assess
safeti
sar
vaccin
observ
whether
antibodi
depend
enhanc
ade
occur
low
level
neutral
antibodi
rhesu
find
puriti
sar
vaccin
hplc
identif
react
convalesc
sera
sar
patient
purifi
sar
vaccin
induc
high
level
neutral
antibodi
prevent
replic
sarscov
monkey
low
level
neutral
antibodi
exacerb
clinic
symptom
observ
immun
monkey
challeng
sarscov
preliminari
anim
trial
side
effect
detect
monkey
immun
purifi
sar
vaccin
either
normal
larg
dose
interpret
purifi
inactiv
sar
vaccin
could
induc
high
level
neutral
antibodi
protect
monkey
challeng
sarscov
sar
vaccin
prepar
studi
appear
safe
monkey
sever
acut
respiratori
syndrom
sar
also
call
infecti
atyp
pneumonia
china
new
emerg
respiratori
infecti
diseas
rapid
transmiss
high
mortal
accord
statist
releas
august
total
clinic
diagnos
case
report
worldwid
caus
death
estim
mortal
novel
coronaviru
sar
coronaviru
sarscov
identifi
pathogen
sar
new
sar
case
report
china
suggest
sar
may
recur
futur
current
medic
strategi
mainli
repli
nonspecif
antivir
support
treatment
suffici
previou
experi
control
infecti
diseas
indic
effici
protect
sar
infect
mass
immun
effect
vaccin
protect
popul
urgent
need
sinc
discoveri
sarscov
caus
sar
inactiv
sarscov
propos
one
prophylact
vaccin
approach
sar
number
studi
coronaviru
vaccin
demonstr
inactiv
vaccin
effect
method
infecti
bronchiti
viru
bovin
coronaviru
although
littl
inform
pathogenesi
sarscov
known
postul
may
feasibl
develop
inactiv
vaccin
sar
present
studi
develop
techniqu
prepar
sar
inactiv
vaccin
investig
immun
respons
protect
effect
induc
vaccin
monkey
data
suggest
vaccin
could
stimul
monkey
produc
high
level
antibodi
could
protect
monkey
sarscov
challeng
result
lay
solid
foundat
earli
phase
human
studi
sarscov
strain
strain
isol
autopsi
lung
tissu
sar
patient
beij
fushan
guangdong
provinc
china
march
complet
sequenc
deposit
genbank
access
number
respect
vero
cell
atcc
provid
nation
vaccin
serum
institut
beij
china
wellgrown
vero
cell
inocul
strain
moi
maintain
serumfre
mem
c
cultur
harvest
cytopath
effect
reach
pass
filter
polypur
silicon
pall
cor
usa
filtrat
collect
ad
vv
shaken
mixtur
kept
c
h
incub
c
h
inactiv
viru
complet
inactiv
viru
concentr
omega
ultrafiltr
unit
suspend
pb
mm
ph
procedur
perform
biosafeti
level
concentr
inactiv
viru
purifi
gel
filtrat
sepharos
fast
flow
ff
amersham
bioscienc
sweden
column
volum
elut
buffer
pb
mm
ph
fraction
outer
void
collect
eluat
contain
sar
antigen
purifi
ion
exchang
chromatographi
aktaexplor
chromatographi
system
use
media
fractogel
emd
dwae
column
equilibr
pb
mm
ph
gel
filtrat
purifi
inactiv
virus
load
elut
pb
contain
nacl
first
elut
peak
contain
viral
antigen
collect
effluent
dilut
accord
protein
concentr
antigen
activ
peak
prepar
purifi
sar
vaccin
puriti
vaccin
analyz
hplc
analysi
two
hundr
microlit
purifi
sar
vaccin
run
tskgel
column
mm
mm
use
mlmin
flow
rate
acquir
hplc
profil
antigen
content
inactiv
sar
vaccin
determin
doubleantibodi
sandwich
elisa
rabbit
immun
sucros
densiti
gradient
zonal
centrifugationpurifi
viru
antigen
prepar
antisarscov
antibodi
first
antibodi
horseradish
peroxidas
label
rabbit
antisarscov
igg
use
second
antibodi
protein
content
purifi
inactiv
sar
vaccin
determin
modif
lowri
method
approxim
l
purifi
sar
vaccin
place
copper
grid
allow
stand
min
residu
fluid
remov
filter
paper
specimen
grid
stain
phosphotungst
acid
min
grid
dri
room
temperatur
observ
transmiss
electron
microscop
sdspage
perform
accord
laemmli
method
electrophoresi
protein
band
gel
transfer
polyvinyl
fluorid
pvdf
membran
millipor
react
convalesc
sera
sar
patient
block
buffer
contain
skim
milk
c
overnight
wash
membran
incub
horseradish
peroxidas
label
rabbit
antihuman
igg
biorad
h
membran
wash
color
develop
cynomologu
macaqu
male
year
old
anim
center
academi
militari
medic
scienc
beij
china
divid
four
group
five
monkey
per
group
group
immun
purifi
vaccin
adjuv
aluminium
hydroxid
aluminium
content
mgml
group
immun
purifi
vaccin
group
immun
unpurifi
inactiv
viru
three
experiment
group
immun
deltoid
muscl
inject
g
day
control
group
inject
supernat
vero
cell
cultur
mlmonkey
monkey
blood
sampl
day
sera
isol
blood
inactiv
c
min
neutral
antibodi
titer
determin
plaqu
reduct
neutral
test
observ
protect
effect
inactiv
vaccin
monkey
group
four
monkey
immun
purifi
inactiv
vaccin
control
group
four
monkey
challeng
ml
sar
strain
log
tcid
ml
nasal
rout
day
prime
immun
specimen
blood
pharynx
swab
stool
collect
day
challeng
neutral
antibodi
sera
determin
viru
isol
rtpcr
also
conduct
monkey
sacrif
day
challeng
lymph
node
lung
spleen
liver
kidney
tissu
collect
rtpcr
patholog
chang
lung
tissu
observ
slide
slice
light
microscop
safeti
evalu
test
antibodi
depend
enhanc
ade
inactiv
sar
vaccin
three
group
rhesu
male
year
old
anim
center
academi
militari
medic
scienc
beij
china
three
rhesu
monkey
per
group
immun
differ
dose
purifi
inactiv
sar
vaccin
gtimemonkey
day
three
monkey
control
group
inject
vero
cell
cultur
blood
sampl
day
neutral
antibodi
determin
monkey
challeng
sarscov
strain
day
dose
tcid
ml
euthan
day
challeng
intern
organ
monkey
sampl
systemat
patholog
chang
observ
assess
possibl
side
effect
larg
dose
purifi
inactiv
sar
vaccin
g
major
organ
monkey
immun
sar
vaccin
deltoid
muscl
inject
hematolog
biochem
patholog
chang
observ
neutral
antibodi
sera
vaccin
monkey
test
plaqu
reduct
neutral
test
prnt
use
vero
cell
brief
heat
inactiv
c
min
sera
dilut
serial
mix
sarscov
ml
incub
c
min
mixtur
ad
vero
cell
flask
absorb
c
min
cover
nutrient
solut
contain
agaros
calf
bovin
serum
streptomycin
dmem
cultur
c
h
dy
neutral
red
flask
incub
c
anoth
h
plaqu
develop
vaccin
monkey
euthan
ether
anaesthesia
lung
liver
kidney
tissu
sampl
place
formaldehyd
follow
convent
dehydr
paraffin
emb
embed
specimen
slice
thick
stain
hematoxyllineosin
observ
light
microscop
cytopath
effect
vero
cell
inocul
sarscov
strain
reach
viru
cultur
harvest
clarifi
inactiv
concentr
ultrafiltr
inactiv
viru
cultur
purifi
sepharos
ff
gel
filtrat
chromatographi
ion
exchang
chromatographi
achiev
higher
puriti
two
step
purif
residu
bovin
serum
albumin
cellular
dna
inactiv
sar
vaccin
less
ngml
respect
ratio
antigen
activityprotein
quantiti
increas
ug
purif
hplc
analysi
show
puriti
sar
vaccin
purifi
compon
inactiv
virus
show
good
antigen
immunogen
mice
data
shown
sarscovlik
particl
could
observ
purifi
vaccin
electron
microscop
shown
fig
molecular
weight
purifi
vaccin
sdspage
analysi
consist
molecular
size
main
structur
protein
sarscov
western
blot
analysi
show
protein
band
react
strongli
convalesc
sera
sar
patient
observ
whether
sar
inactiv
vaccin
induc
sarsspecif
neutral
antibodi
cynomolo
gu
macaqu
immun
adjuvantcontain
purifi
vaccin
purifi
vaccin
unpurifi
vaccin
sera
sampl
differ
time
measur
neutral
antibodi
titer
shown
fig
week
day
first
boost
larg
increas
neutral
antibodi
observ
sera
three
immun
group
neutral
antibodi
titer
immun
group
peak
week
second
boost
week
prime
antibodi
level
also
increas
rapidli
last
boost
observ
period
result
show
neutral
antibodi
level
adjuvantcontain
purifi
vaccin
group
higher
last
longer
two
group
quantiti
neutral
antibodi
product
time
antibodi
level
mainten
show
appar
differ
purifi
vaccin
group
without
adjuv
unpurifi
vaccin
group
antibodi
level
unpurifi
vaccin
group
appear
decreas
somewhat
faster
result
show
purifi
unpurifi
sar
vaccin
induc
high
level
sarscov
specif
neutral
antibodi
monkey
thu
demonstr
high
immunogen
fig
antisarscov
neutral
antibodi
titer
monkey
sera
elicit
differ
inactiv
sar
vaccin
cynomologu
macaqu
immun
adjuvantcontain
purifi
vaccin
purifi
vaccin
unpurifi
vaccin
supernat
vero
cell
cultur
mlmonkey
control
deltoid
muscl
inject
g
day
monkey
blood
sampl
day
neutral
antibodi
titer
determin
plaqu
reduct
neutral
test
present
geometr
mean
n
observ
protect
effect
purifi
inactiv
sar
vaccin
monkey
aforement
two
anim
group
purifi
vaccin
group
unvaccinatedcontrol
group
four
monkey
per
group
challeng
sar
strain
nasal
rout
day
prime
immun
result
show
sarscov
isol
monkey
immun
group
control
group
sarscov
isol
pharynx
swab
inocul
two
four
monkey
day
challeng
rtpcr
amplif
tissu
sampl
autopsi
monkey
day
challeng
show
lymph
node
lung
spleen
kidney
tissu
four
monkey
immun
group
neg
control
group
posit
rate
rtpcr
amplif
lymph
node
spleen
lung
kidney
tissu
respect
result
indic
inactiv
sar
vaccin
may
inhibit
propag
sarscov
monkey
patholog
examin
challeng
monkey
show
two
four
anim
unvaccinatedcontrol
group
display
moder
mild
interstiti
pneumonia
two
four
immun
group
normal
remain
two
immun
monkey
show
mild
interstiti
pneumonia
without
patholog
chang
tissu
result
suggest
purifi
inactiv
sar
vaccin
protect
effect
monkey
shown
fig
neutral
antibodi
level
immun
group
peak
day
last
immun
ie
day
prime
immun
decreas
gradual
thereaft
day
prime
immun
neutral
antibodi
titer
sera
four
immun
monkey
drop
rang
howev
antibodi
level
immun
group
increas
significantli
week
challeng
indic
inactiv
sar
vaccin
produc
immun
memori
monkey
rhesu
monkey
immun
differ
dose
purifi
inactiv
sar
vaccin
hematolog
biochem
index
show
chang
anim
includ
nine
monkey
immun
group
three
monkey
unvaccinatedcontrol
group
data
shown
fever
observ
monkey
h
inject
sar
vaccin
appetit
mental
state
anim
maintain
normal
examin
whether
differ
antibodi
level
produc
differ
dose
vaccin
induc
correspond
antibodi
depend
enhanc
monkey
immun
group
unvaccinatedcontrol
group
challeng
sarscov
strain
nasal
rout
day
prime
immun
fig
result
show
clinic
symptom
detect
immun
monkey
bodi
temperatur
hemogram
normal
day
immun
differ
dose
inactiv
vaccin
systemat
patholog
observ
light
microscop
show
abnorm
intern
organ
monkey
histopatholog
observ
indic
monkey
unvaccinatedcontrol
group
show
obviou
interstiti
pneumonia
interstiti
pneumonia
also
observ
immun
group
obvious
milder
unvaccinatedcontrol
group
among
monkey
low
dose
group
especi
low
level
neutral
antibodi
patholog
chang
milder
unvaccinatedcontrol
group
result
show
neither
infect
enhanc
immunopatholog
exacerb
observ
low
neutral
antibodi
titer
monkey
immun
higher
dose
gtimemonkey
bodi
temperatur
breath
appetit
mental
state
biochem
index
normal
data
shown
abnorm
observ
major
organ
lung
liver
kidney
etc
result
indic
purifi
sar
vaccin
prepar
present
studi
safe
monkey
isol
propag
high
titer
sarscov
vero
cell
provid
solid
foundat
develop
inactiv
sar
vaccin
draw
previou
research
current
avail
technic
platform
result
inactiv
viral
vaccin
develop
concentr
purif
techniqu
sar
vaccin
inactiv
sar
vaccin
produc
standard
qualiti
control
show
high
puriti
immunogen
vaccin
could
also
induc
high
level
neutral
antibodi
date
sever
approach
develop
sar
vaccin
report
includ
inactiv
vaccin
recombin
adenoviru
vaccina
viru
dna
vaccin
vaccin
could
induc
product
specif
antisar
antibodi
activ
ctl
respons
could
induc
protect
immun
mice
recombin
adenoviru
contain
gene
encod
protein
fragment
fulllength
n
also
prove
abl
induc
protect
immun
monkey
data
studi
inactiv
sar
vaccin
show
highest
specif
ab
titer
mice
monkey
suggest
high
immunogen
inactiv
vaccin
unlik
studi
inactiv
vaccin
sar
inactiv
sar
vaccin
produc
standard
qualiti
control
observ
immunogen
monkey
show
unpurifi
inactiv
sar
vaccin
induc
almost
level
neutral
antibodi
purifi
vaccin
even
unpurifi
product
could
appli
clinic
use
high
content
protein
impur
might
induc
underli
pyrogen
fever
studi
also
demonstr
vaccin
adjuv
aluminium
could
induc
higher
antibodi
product
sarscov
clinic
safeti
concern
possibl
side
effect
human
preclud
use
adjuvantcontain
purifi
vaccin
evalu
immun
protect
efficaci
test
thu
select
purifi
inactiv
sar
vaccin
detail
safeti
efficaci
studi
previou
sar
vaccin
studi
group
challeng
perform
monkey
high
level
neutral
antibodi
approach
inform
popul
immun
studi
challeng
monkey
lower
level
neutral
antibodi
consist
gener
popul
vaccin
context
find
low
neutral
antibodi
stage
challeng
promis
result
show
sarscov
could
replic
relev
tissu
specif
lymph
node
spleen
histopatholog
examin
lung
tissu
show
moder
mild
interstiti
pneumonia
develop
control
monkey
patholog
evid
found
immun
monkey
doserespons
relationship
import
criterion
studi
efficaci
vaccin
result
neutral
test
rtpcr
autopsi
show
higher
level
neutral
antibodi
induc
higher
dose
vaccin
could
decreas
sarscov
viral
load
pneumon
chang
compar
control
monkey
challeng
anim
studi
need
quantifi
relationship
vaccin
dose
protect
efficaci
accur
establish
threshold
safeti
rna
virus
known
induc
antibodi
depend
enhanc
exacerb
diseas
immun
popul
expos
dengu
viru
infect
ade
therefor
signific
obstacl
inactiv
vaccin
develop
studi
safeti
efficaci
focus
occurr
ade
sarscov
immun
monkey
challeng
neutral
antibodi
decreas
low
level
mimick
situat
immun
popul
preliminari
result
show
obviou
ade
phenomena
detect
immun
monkey
challeng
sarscov
strain
also
level
neutral
antibodi
immun
monkey
increas
sharpli
sar
onset
indic
immun
memori
establish
vaccin
monkey
monkey
wide
studi
anim
model
sar
research
although
studi
purifi
inactiv
sar
vaccin
base
monkey
anim
model
unabl
conclud
monkey
ideal
anim
sar
vaccin
evalu
studi
monkey
appear
letharg
sever
day
inocul
develop
diffus
alveolar
damag
similar
sar
patient
without
typic
clinic
symptom
anim
model
may
elicit
differ
reaction
vaccin
studi
use
neutral
antibodi
level
interstiti
pneumonia
two
main
indic
immunogen
protect
efficaci
purifi
inactiv
sar
vaccin
result
indic
purifi
inactiv
sar
vaccin
develop
could
induc
high
level
neutral
antibodi
protect
monkey
sarscov
challeng
administ
safe
monkey
taken
togeth
find
provid
solid
foundat
clinic
research
inactiv
sar
vaccin
continu
research
sever
immunopatholog
reaction
undertaken
futur
preclin
research
clinic
trial
